These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36700402)

  • 21. Immunomodulating Agents as Antipruritics.
    Erickson S; Nahmias Z; Rosman IS; Kim BS
    Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aquagenic pruritus indicates increased risks in patients with myeloproliferative neoplasms.
    Legat FJ
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1095-1096. PubMed ID: 37171288
    [No Abstract]   [Full Text] [Related]  

  • 23. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
    Dasanu CA; Schwartz RA; Bauer F; Davis LK; Silver JS; Reale MA
    Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
    [No Abstract]   [Full Text] [Related]  

  • 24. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement.
    Wilberger AC; McMahon B; Ewalt MD
    Leuk Lymphoma; 2019 Apr; 60(4):1095-1097. PubMed ID: 30277124
    [No Abstract]   [Full Text] [Related]  

  • 25. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.
    Telford N; Alexander S; McGinn OJ; Williams M; Wood KM; Bloor A; Saha V
    Blood Cancer J; 2016 Apr; 6(4):e412. PubMed ID: 27058227
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19 and myeloproliferative neoplasms: some considerations.
    Kamaz B; Mullally A
    Leukemia; 2021 Jan; 35(1):279-281. PubMed ID: 33106624
    [No Abstract]   [Full Text] [Related]  

  • 27. [The cutting edge of medicine: pathophysiology and treatment of myeloproliferative neoplasms].
    Komatsu N
    Nihon Naika Gakkai Zasshi; 2014 Feb; 103(2):440-9. PubMed ID: 24724385
    [No Abstract]   [Full Text] [Related]  

  • 28. JAK2 inhibitors and myeloproliferative neoplasms.
    Verstovsek S
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):878-80, 896. PubMed ID: 19209137
    [No Abstract]   [Full Text] [Related]  

  • 29. Unbalanced jumping translocation involving 3q in myeloproliferative disease.
    McGrattan P; Humphreys M; Hull D
    Med Oncol; 2009; 26(2):251-5. PubMed ID: 18509766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems?
    Rizzari C; Malberti R; Dell'Orto M; Milani M; Jankovic M; Ferrari E; Conter V
    Med Pediatr Oncol; 1999 Jun; 32(6):453-4. PubMed ID: 10358708
    [No Abstract]   [Full Text] [Related]  

  • 31. Maculopapular Cutaneous Mastocytosis Successfully Treated with Omalizumab.
    Tampouratzi L; Kanni T; Katsantonis J; Douvali T
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):60-61. PubMed ID: 34477069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent chronic myeloid leukemia and CALR-mutated chronic myeloproliferative neoplasm.
    Guidotti F; Gardellini A; Feltri M; Zancanella M; Saccà V; Alberio F; Ambrosiani L; Turrini M
    Blood Cells Mol Dis; 2020 Mar; 81():102395. PubMed ID: 31816513
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
    Hinojosa T; Lewis DJ; Vangipuram R; Safeer L; Mui UN; Haley C; Konoplev S; Tyring SK
    Dermatol Ther; 2019 May; 32(3):e12848. PubMed ID: 30697883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12).
    Invernizzi R; Benatti C; Travaglino E; Girino M; Bernasconi P; Loni C; Ascari E
    Haematologica; 2004 Feb; 89(2):239-41. PubMed ID: 15003903
    [No Abstract]   [Full Text] [Related]  

  • 35. The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms.
    Holik H; Lucijanić M; Krečak I
    Ann Hematol; 2024 May; 103(5):1783-1785. PubMed ID: 38472363
    [No Abstract]   [Full Text] [Related]  

  • 36. Pyoderma gangrenosum and myeloproliferative neoplasms.
    Langabeer SE
    Clin Exp Dermatol; 2023 Apr; 48(5):555-556. PubMed ID: 36702807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular biology and new drug therapy for myeloproliferative neoplasm].
    Kitanaka A; Shide K; Shimoda K
    Rinsho Ketsueki; 2013 Oct; 54(10):1697-703. PubMed ID: 24064819
    [No Abstract]   [Full Text] [Related]  

  • 38. Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm.
    Sabbagh S; Jarrah K; Bou-Fakhredin R; Saadeh D; Taher AT
    Ann Hematol; 2022 Jul; 101(7):1595-1596. PubMed ID: 35150295
    [No Abstract]   [Full Text] [Related]  

  • 39. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain.
    Tefferi A
    Am J Hematol; 2010 Feb; 85(2):93-4. PubMed ID: 20052751
    [No Abstract]   [Full Text] [Related]  

  • 40. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
    Barrios DM; Phillips GS; Geisler AN; Trelles SR; Markova A; Noor SJ; Quigley EA; Haliasos HC; Moy AP; Schram AM; Bromberg J; Funt SA; Voss MH; Drilon A; Hellmann MD; Comen EA; Narala S; Patel AB; Wetzel M; Jung JY; Leung DYM; Lacouture ME
    Ann Oncol; 2021 Jun; 32(6):736-745. PubMed ID: 33667669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.